A randomised trial of Mycobacterium w in critically ill patients with COVID-19: ARMY-1

A randomised trial of Mycobacterium w in critically ill patients with COVID-19: ARMY-1

Purpose We investigated whether Mycobacterium w (Mw), an immunomodulator, would improve clinical outcomes in coronavirus disease 2019 (COVID-19). Methods We conducted an exploratory, randomised, double-blind, placebo-controlled trial of hospitalised subjects with severe COVID-19 (pulmonary infiltrat...

Full description

Bibliographic Details
Main Authors: Inderpaul Singh Sehgal, Randeep Guleria, Sarman Singh, Mohammad Sabah Siddiqui, Ritesh Agarwal, ARMY trial study group:, Anant Mohan, A. Jindal, A. Bhalla, Kamal Kajal, Pankaj Malhotra, Goverdhan Dutt Puri, Sagar Khadanga, Rajnish Joshi, S. Saigal, Nitin M. Nagarkar, Vikas Suri, Sushma Bhatnagar, Pawan Tiwari, Mini P. Singh, Laxmi Narayana Yaddanapudi, Sourab Mittal
Format: Article
Language:English
Published: European Respiratory Society 2021-04-01
Series:ERJ Open Research
Online Access:http://openres.ersjournals.com/content/7/2/00059-2021.full

Internet

http://openres.ersjournals.com/content/7/2/00059-2021.full

Similar Items